Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

May 20, 2023

Study Completion Date

May 20, 2023

Conditions
Cardiac Allograft Vasculopathy
Interventions
DRUG

Evolocumab

420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.

DRUG

Placebo

Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.

Trial Locations (5)

2100

Department of Cardiology, Rigshospitalet, Copenhagen

8200

Department of Cardiology, Aarhus University Hospital, Skejby

22185

The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund

00029

Helsinki University Hospital Heart and Lung Center, Helsinki

SE-41345

Department of Cardiology, Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Helsinki University Central Hospital

OTHER

lead

Lars Gullestad

OTHER

NCT03734211 - Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients | Biotech Hunter | Biotech Hunter